These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 31597402

  • 21. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW, Zhou FJ, Han H, Qin ZK, Yu SL, Li YH, Ye YL, Teng XY.
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [Abstract] [Full Text] [Related]

  • 22. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [Abstract] [Full Text] [Related]

  • 23. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
    von Eyben FE, Blaabjerg O, Madsen EL, Petersen PH, Smith-Sivertsen C, Gullberg B.
    Eur J Cancer; 1992 Dec; 28(2-3):410-5. PubMed ID: 1375486
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W.
    Eur J Cancer; 1993 Dec; 29A(7):961-5. PubMed ID: 7684597
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
    Konneh B, Lafin JT, Howard J, Gerald T, Amini A, Savelyeva A, Woldu SL, Lewis CM, Jia L, Margulis V, Coleman N, Scarpini C, Frazier AL, Murray MJ, Amatruda JF, Bagrodia A.
    Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery.
    Vugrin D, Friedman A, Whitmore WF.
    Cancer; 1984 Mar 15; 53(6):1440-5. PubMed ID: 6198071
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours.
    Dieckmann KP, Spiekermann M, Balks T, Flor I, Löning T, Bullerdiek J, Belge G.
    Br J Cancer; 2012 Nov 06; 107(10):1754-60. PubMed ID: 23059743
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Germ cell tumour subtypes display differential expression of microRNA371a-3p.
    Vilela-Salgueiro B, Barros-Silva D, Lobo J, Costa AL, Guimarães R, Cantante M, Lopes P, Braga I, Oliveira J, Henrique R, Jerónimo C.
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun 05; 373(1748):. PubMed ID: 29685967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.